View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
September 18, 2018updated 12 Jul 2022 1:12pm

GamaMabs Pharma doses first patient in Phase ll trial of GM102

GamaMabs Pharma has dosed the first patient in its Phase ll clinical trial of GM102 and in combination with Trifluridine/Tipiracil (Lonsurf) to treat patients with advanced or metastatic colorectal cancer (CRC).

GamaMabs Pharma has dosed the first patient in its Phase ll clinical trial of GM102 and in combination with Trifluridine/Tipiracil (Lonsurf) to treat patients with advanced or metastatic colorectal cancer (CRC).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The European multicentre, two-parallel, non-randomised trial aims to enrol two cohorts of patients.

Cohort one will include patients who have progressed after at least two lines of prior systemic therapies for metastatic or locally advanced disease and have received all prior available therapies, while the cohort two will include subjects to administer Lonsurf.

The trial will evaluate objective response rates, immunological changes in the tumour microenvironment, progression-free and overall survival rates of the enrolled patients.

It is based on results of collaborative research with various European academic research centres and hospitals.

“The C201 study will investigate the anti-tumour activity of GM102 in this new indication and its potential synergism with Lonsurf for patients who have progressed on prior therapies.”

The results showed various Anti-Mullerian hormone receptor type 2 (AMHRII) expression in human CRC tumours and a significant expression of the target on tumour cells at the membrane level.

GamaMabs Pharma chief medical officer Isabelle Tabah-Fisch said: “The C201 study will investigate the anti-tumour activity of GM102 in this new indication and its potential synergism with Lonsurf for patients who have progressed on prior therapies.

“Most CRC tumours express moderate-to-large macrophage infiltration. GM102 therefore has a potential to enhance macrophage phagocytosis on tumour cells in addition to acting synergistically with Lonsurf.

“This is a key step in the development of our molecule, which has already shown excellent tolerability in patients with gynecological cancers and first signs of activity in the first patients in the phase la/lb C101 study, recently presented at the ASCO 2018 conference.”

GM102 is a glyco-engineered (low-fucose) monoclonal antibody designed to target tumour antigen AMHRII, which is re-expressed in around 70% of CRC patients.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena